← Analysis page  ·  Pieter Slegers hub  ·  Research hub

Actionable insights — How to Identify Great Compounders

Estimating a company's own growth rate from two numbers rather than a forecast, and the price-insensitivity test that tells you whether a business can raise prices every year without anyone noticing.
2026-AUG-04 · Compounding Quality (Substack) · Pieter Slegers / Team Compounding Quality · read ↗ · full analysis · transcript
How to read this page: a five-minute teaching post, so there are only a handful of methods — but the first one is the arithmetic underneath most of the rest of this archive, and the Diploma case supplies two screens that transfer directly to other roll-ups. Written post, so no timestamps.

1. Derive a company's sustainable growth rate from ROIC × reinvestment rate, not from a forecast

The repeatable method
  1. Take the return on invested capital — the profit generated per dollar of capital already in the business.
  2. Take the reinvestment rate — the share of profits the business can actually put back to work inside itself.
  3. Multiply them. That product is the rate at which the business can grow using only its own cash, with no assumption about the market or the multiple.
  4. Compare that number with what analysts are forecasting. A forecast materially above ROIC × reinvestment requires either an acquisition programme or outside capital — find out which.
  5. Screen on both terms at once: a high return that cannot be redeployed and a large redeployment at a poor return both fail.
Here: "Growth Rate = High ROIC × High Reinvestment." A 25% ROIC business reinvesting 40% compounds at 10%; a 10% ROIC business reinvesting 65% compounds at 6.5% — "despite reinvesting much more capital." Stated threshold: "companies with a high ROIC (> 15%) that reinvest a lot in organic growth."
Watch for

2. Test pricing power by the customer's cost share, not by brand strength

The repeatable method
  1. For each product, estimate what fraction of the customer's total spend it represents.
  2. Ask what happens to the customer if the product fails or is unavailable — the cost of getting it wrong.
  3. The combination of a tiny cost share and a large failure cost is what allows above-inflation price rises to go unchallenged, year after year.
  4. Verify by looking for a track record of annual price increases without volume loss, rather than by asking whether the brand is well known.
  5. Apply the same test to every subsidiary in a roll-up — the group's pricing power is only as good as the individual products'.
Here: DPLM.L raises prices "by 3-5% every year. Customers barely notice because these products account for just 0.2% of their total costs" — while a wrong bolt on a 787 or a non-sterile valve on an MRI machine is an unacceptable outcome. No consumer brand is involved at all.
Watch for

3. Screen serial acquirers on entry multiple and post-deal autonomy, not on deal count

The repeatable method
  1. Find the multiple of earnings the acquirer habitually pays. Anything in the high single digits against a group trading far higher is arbitrage on its own.
  2. Check whether the sellers stay: a founder retained with real autonomy is the cheapest form of management the acquirer will ever buy.
  3. Identify the value added after the deal, and require it to be specific — cross-selling, centralised purchasing, pricing — not "synergies".
  4. Confirm the target pool is deep and fragmented enough that the programme can continue for decades rather than years.
  5. Then check the arithmetic of insight 1 holds on the acquired capital, not just the legacy business.
Here: "They buy family-run businesses at 6-8x earnings, leave the founders in charge, and give them full autonomy. Over time, they cross-sell products, consolidate purchasing, and raise prices by 3-5% every year." Hundreds of subsidiaries, each "tiny, local, and deeply embedded in its supply chain" — a pool that has supported 18.9% a year for 34 years.
Watch for

4. Treat holding period as an input to the return, not a consequence of it

The repeatable method
  1. Before buying, state how long the compounding argument needs to run to produce the return you want.
  2. Check that nothing in your own circumstances — cash needs, mandate, reporting cadence — would force a sale inside that window.
  3. Judge the position on whether the business's own growth arithmetic still holds, not on the price path.
  4. Record the intended holding period alongside the purchase, so a later exit has to argue against something written down.
Here: "It's not about a Magic Formula or big secrets. It's all about being patient," followed by the Munger card: "The big money is not in the buying and the selling, but in the waiting." The Diploma record that anchors the post is measured over 34 years — the arithmetic and the patience are the same claim stated twice.
Watch for

Methods distilled from the archived Compounding Quality post for personal study. Not investment advice.